about
Expression of the core exon-junction complex factor eukaryotic initiation factor 4A3 is increased during spatial exploration and striatally-mediated learningEvaluating an etiologically relevant platform for therapy development for temporal lobe epilepsy: effects of carbamazepine and valproic acid on acute seizures and chronic behavioral comorbidities in the Theiler's murine encephalomyelitis virus mouseNeuronal Injury, Gliosis, and Glial Proliferation in Two Models of Temporal Lobe Epilepsy.The GABA synapse as a target for antiepileptic drugs: a historical overview focused on GABA transporters.How clinical development can, and should, inform translational science.Disease modification in epilepsy: from animal models to clinical applications.Glutamatergic Mechanisms Associated with Seizures and Epilepsy.Neuroinflammation in epileptogenesis: Insights and translational perspectives from new models of epilepsy.Acute cognitive impact of antiseizure drugs in naive rodents and corneal-kindled mice.Acute treatment with minocycline, but not valproic acid, improves long-term behavioral outcomes in the Theiler's virus model of temporal lobe epilepsy.Disruption of subcellular Arc/Arg 3.1 mRNA expression in striatal efferent neurons following partial monoamine loss induced by methamphetamine.Validation of a Preclinical Drug Screening Platform for Pharmacoresistant Epilepsy.A companion to the preclinical common data elements for pharmacologic studies in animal models of seizures and epilepsy. A Report of the TASK3 Pharmacology Working Group of the ILAE/AES Joint Translational Task ForceLamotrigine-resistant corneal-kindled mice: A model of pharmacoresistant partial epilepsy for moderate-throughput drug discoveryIntravenously Administered Ganaxolone Blocks Diazepam-Resistant Lithium-Pilocarpine-Induced Status Epilepticus in Rats: Comparison with AllopregnanoloneCannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy modelsRepeated Intraperitoneal Administration of Low-Concentration Methylcellulose Leads to Systemic Histologic Lesions Without Loss of Preclinical PhenotypeHow do we choose the appropriate animal model for antiseizure therapy development?
P50
Q28578288-5D9C1FB2-5C32-4414-9F49-677BBE7E7753Q35531800-D429881E-7618-4489-BDBC-27424D9D6085Q37228255-B4F9C52A-5345-4DB9-B704-4C81DAA1A5A1Q38195817-0C22F267-5703-435E-BA12-B07314FB6805Q38274357-E10B7CDD-B2EF-442A-8842-C4C7A7BA6538Q38450069-99FADFAF-A32D-4D6E-B43C-674C62186E04Q38535033-4F19E77C-66F8-46D5-BFAF-38083D2567BEQ38694553-81F13D8E-58A4-40B7-B62A-88B7545AE32DQ39552330-2C09E378-E226-417E-B74D-11AA34F9350DQ40507200-B438E8B3-1394-49B5-B64F-A008A5CF0740Q41317144-03A1BAB3-CF71-48F3-BC17-564C831680CAQ47416325-516096C9-C6A7-4323-A395-EECDD0F149BDQ59137534-FFDE4B33-A409-4CA3-BA52-B6EC63CB0463Q88639503-C951B86E-DD2A-4DC5-B9B2-1D73BAD3A28EQ90524414-04A26943-88CB-4A59-9529-7283C229B44DQ90768765-30FBCA48-F4F7-4801-B647-40F0880011CAQ92376853-36CE25B5-1BFB-4C0F-BACE-DE85EF9F605FQ93082819-856A4FD3-F42E-4094-8928-3A3C5020D3F7
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Melissa L Barker-Haliski
@ast
Melissa L Barker-Haliski
@en
Melissa L Barker-Haliski
@es
Melissa L Barker-Haliski
@nl
type
label
Melissa L Barker-Haliski
@ast
Melissa L Barker-Haliski
@en
Melissa L Barker-Haliski
@es
Melissa L Barker-Haliski
@nl
prefLabel
Melissa L Barker-Haliski
@ast
Melissa L Barker-Haliski
@en
Melissa L Barker-Haliski
@es
Melissa L Barker-Haliski
@nl
P106
P1153
55382553600
P31
P496
0000-0002-8175-0553